insulin therapy

Description Results NMA

noctural hypoglycemia 0.51 [0.40; 0.66]

symptomatic hypoglycemia 0.86 [0.74; 0.99]

severe hypoglycemia 0.75 [0.27; 2.09]

any hypoglycemia 0.96 [0.87; 1.05]

severe hypoglycemia 1.36 [0.51; 3.62]

noctural hypoglycemia 0.78 [0.62; 0.98]

symptomatic hypoglycemia 0.92 [0.81; 1.05]

noctural hypoglycemia 0.56 [0.40; 0.79]

symptomatic hypoglycemia 0.84 [0.72; 0.98]

severe hypoglycemia 0.59 [0.22; 1.57]

noctural hypoglycemia 0.50 [0.34; 0.73]

symptomatic hypoglycemia 0.64 [0.53; 0.77]

severe hypoglycemia 1.62 [0.39; 6.72]

severe hypoglycemia NaN [NaN; NaN]

severe hypoglycemia 0.00 [0.00; NaN]

noctural hypoglycemia 0.57 [0.26; 1.25]

symptomatic hypoglycemia 0.76 [0.53; 1.11]

any hypoglycemia 0.56 [0.50; 0.62]

noctural hypoglycemia 0.27 [0.14; 0.53]

severe hypoglycemia ∞ [NaN; ∞]

noctural hypoglycemia 0.13 [0.02; 0.94]

any hypoglycemia 0.25 [0.06; 1.09]

noctural hypoglycemia 0.43 [0.26; 0.68]

symptomatic hypoglycemia 0.79 [0.62; 1.02]

severe hypoglycemia NaN [NaN; NaN]

any hypoglycemia 1.15 [0.66; 2.00]

morning insulin glargine (n=463)

vs.

bedtime insulin glargine (n=232)

open

Sample size: 463/232

Primary endpoint:

FU duration: 24 weeks

bedtime glargine (n=367)

vs.

NPH (n=389)

open

Sample size: 367/389

Primary endpoint:

FU duration: 24 weeks

glargine (n=259)

vs.

(n=259)

Sample size: 259/259

Primary endpoint:

FU duration: 28 weeks

glargine (n=231)

vs.

(n=250)

Sample size: 231/250

Primary endpoint:

FU duration: 24 weeks

glargine (n=293)

vs.

(n=285)

Sample size: 293/285

Primary endpoint:

FU duration: 52 weeks

glargine (n=61)

vs.

(n=49)

Sample size: 61/49

Primary endpoint:

FU duration: 36 weeks

glargine (n=52)

vs.

(n=48)

Sample size: 52/48

Primary endpoint:

FU duration: 28 weeks

glargine (n=220)

vs.

(n=223)

Sample size: 220/223

Primary endpoint:

FU duration: 24 weeks

detemir (n=334)

vs.

(n=164)

Sample size: 334/164

Primary endpoint:

FU duration: 20 weeks

glargine (n=16)

vs.

(n=8)

Sample size: 16/8

Primary endpoint:

FU duration: 12 weeks

glargine; (n=214)

vs.

(n=208)

Sample size: 214/208

Primary endpoint:

FU duration: 52 weeks

glargine (n=31)

vs.

(n=31)

Sample size: 31/31

Primary endpoint:

FU duration: 26 weeks

single injection of glulisine before breakfast (n=-9)

vs.

single injection of glulisine before their main mealtime (breakfast, lunch or dinner); (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

multiple daily injection using insulin lispro and insulin glargine (n=-9)

vs.

continuous subcutaneous insulin infusion using insulin lispro (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

bedtime glargine (n=-9)

vs.

NPH once daily (n=-9)

open-label

Parallel groups

Sample size: -9/-9

Primary endpoint:

FU duration:

bedtime insulin glargine (n=-9)

vs.

bedtime NPH insulin (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

HbA1c <7% 2.56 [0.95; 6.86]

basal+bolus (single dose of insulin glulisine immediately prior to the main meal) (n=49)

vs.

basal insulin (glargin) (n=57)

open-label

Parallel groups

Sample size: 49/57

Primary endpoint:

FU duration: 3 months

AVE0010 (10,15 and 20 µg) in association with basal insulin, with or without metformin (n=328)

vs.

placebo on top basal insulin (n=167)

the type of basal insulin used during the trial is not specified in the available document

double-blind

Parallel groups

Sample size: 328/167

Primary endpoint: change from baseline in HbA1c

FU duration: 24 weeks